API Import Requirements: USA, EU, Brazil, Mexico & Africa — A Market-by-Market Regulatory Guide for Indian Exporters

Introduction: Why API Import Requirements Differ Dramatically by Market — and Why That Matters for Indian Exporters

An Indian API manufacturer receives two purchase orders on the same day. One is from a US-based generic drug formulator. The other is from a Nigerian pharmaceutical company. The compound being shipped — Ferrous Fumarate — is identical in both cases. Same CAS number. Same pharmacopoeial grade. Same batch.

But the documentation, regulatory registration, and pre-shipment compliance requirements for these two shipments are entirely different. The US buyer requires FDA foreign establishment registration and drug listing under 21 CFR 207. The Nigerian buyer requires an NAFDAC API Import Permit, a Drug Master File submission, and sourcing from a WHO-prequalified or SRA-certified facility. Treating these requirements as interchangeable — or assuming that compliance in one market transfers to another — is the fastest way to have a shipment detained, rejected, or refused at port.

India's pharmaceutical exports reached $30.5 billion in FY 2024–25, reaching 191 countries, with roughly 50% directed to highly regulated markets including the US and EU. For Indian API manufacturers, understanding the import requirements of each destination market is not a regulatory formality — it is the commercial foundation on which export business is built.

This guide explains the verified, current API import requirements for five major markets — the United States, the European Union, Brazil, Mexico, and Africa (Nigeria and South Africa) — sourced directly from official regulatory authority publications, with document-by-document requirements a buyer or exporter needs to know before the first shipment leaves the factory gate.

1. Summary Comparison: API Import Requirements by Market

2. USA — FDA Requirements for Importing Active Pharmaceutical Ingredients

The Governing Regulatory Framework

APIs imported or offered for import into the United States must comply with all applicable requirements under the Food, Drug and Cosmetic (FD&C) Act and Title 21 of the Code of Federal Regulations (21 CFR).

Requirement 1: Foreign Establishment Registration

Foreign establishments that manufacture, repack, relabel, or salvage APIs that are imported or offered for import into the US must register with FDA under Section 510(i) of the FD&C Act and 21 CFR 207.17.

Additionally, foreign establishments required to register with FDA must list all known importers in their registration, per Section 510(i)(1)(A) of the FD&C Act and 21 CFR 207.25(h)(2).

Critical 2022 update — FDORA: On December 29, 2022, the Consolidated Appropriations Act 2023 was signed into law, containing the Food and Drug Omnibus Reform Act (FDORA). This amended Section 510(i) (21 U.S.C. 360(i)) to require registration of foreign establishments even if they only distribute their API to another foreign establishment that subsequently processes and imports the finished drug into the US. This directly closes a loophole under which many upstream foreign API manufacturers previously avoided FDA registration.

Requirement 2: Drug Listing

Foreign drug manufacturers, repackers, relabelers, and salvagers are required to list all their commercially distributed drugs, including APIs, with FDA under Section 510(j) of the FD&C Act and 21 CFR 207.41. At the time of importation, the listing provided must be the manufacturer's API listing.

Requirement 3: US FDA Agent Designation

All foreign API manufacturers must designate a United States FDA Agent as part of their registration. This is a US-based individual or company responsible for communications with FDA on behalf of the foreign establishment — not merely a commercial representative, but a formally designated regulatory contact.

Requirement 4: Labeling Compliance

APIs are inherently misbranded under Section 502(f)(1) of the FD&C Act because their labeling does not bear "adequate directions for use" by a consumer. APIs must therefore comply with specific labeling requirements under 21 CFR 201.122 to be eligible for a labeling exemption at the time of importation.

What This Means for Indian API Exporters Targeting the US Market

Indian API manufacturers supplying to US-registered drug manufacturers must ensure FDA foreign establishment registration is in place and current before the first shipment. The FDORA change (2022) is particularly significant — it means Indian API manufacturers who supply Indian or third-country formulators whose finished drug products ultimately reach the US market are now within FDA's registration scope, even if they have never directly shipped to the US.

3. European Union — EMA and the Falsified Medicines Directive

The Written Confirmation Requirement

The most important EU-specific requirement for foreign API exporters is the Written Confirmation introduced under the Falsified Medicines Directive (FMD). From July 2, 2013, all active substances manufactured outside the EU and imported into the EU must be accompanied by a written confirmation from the competent authority of the exporting country confirming that:

1. The standards of GMP at the manufacturing plant are equivalent to those in the EU
2. The competent authority of the exporting country will communicate any GMP non-compliance to the EU without delay

For India: The Drugs Controller General of India (DCGI) under the Central Drugs Standard Control Organisation (CDSCO) is the Indian competent authority that issues Written Confirmations for Indian API manufacturers exporting to the EU.

Who Is Exempt from the Written Confirmation Requirement?

Four countries are currently exempt from the Written Confirmation requirement on grounds that their regulatory and monitoring standards on GMP are considered equivalent to those of the EU: the United States, Japan, Australia, and Switzerland. India is not on this exemption list, meaning every shipment of Indian-manufactured APIs to the EU must carry a valid Written Confirmation from CDSCO/DCGI.

EudraGMDP — The EU's Public GMP Database

The EudraGMDP database (eudragmdp.ema.europa.eu) is a publicly accessible EU database containing manufacturing and import authorizations, API manufacturer registrations, GMP certificates, and non-compliance statements. EU importers and finished-product manufacturers use this database to verify the GMP status of their API suppliers before using them in licensed drug products.

Indian API manufacturers that have been inspected by EU competent authorities and received a GMP certificate will have their status reflected in EudraGMDP — a significant commercial advantage for exporting to EU markets.

2025 Update: No Further General Extension of GMP Certificates

On February 24, 2025, the European Medicines Agency published an update confirming that the general extension of GMP and GDP certificates — which had been granted during and after the COVID-19 public health emergency — would no longer apply from 2025. National competent authorities may still decide on case-by-case extensions, but the blanket extension is over.

This means Indian API manufacturers whose EU GMP certificates lapsed during the pandemic and were covered by the general extension must now either complete a fresh inspection or obtain a case-by-case extension from the relevant national authority.

EU Import Authorization and the Qualified Person (QP)

EU-based pharmaceutical manufacturers importing APIs must hold a Manufacturing/Import Authorisation from their national competent authority. They are legally responsible for ensuring their API supplier's GMP compliance — the Qualified Person (QP) at the EU importing site bears personal legal responsibility for confirming that each API batch was manufactured in compliance with EU GMP standards equivalent.

4. Brazil — ANVISA Requirements for API Imports

The CADIFA System

Brazil's primary mechanism for API import compliance is the CADIFA — Carta de Adequabilidade do Dossiê de Insumo Farmacêutico Ativo — introduced in April 2020. A CADIFA is a letter from ANVISA confirming the acceptance of an API dossier (Drug Master File), serving as proof of compliance with Good Manufacturing Practices for API production in Brazil.

A key distinction: unlike most other markets, the foreign API manufacturer can apply for CADIFA directly with ANVISA without engaging a Brazilian regulatory agent. Once granted, the CADIFA can be used to support multiple drug product registration applications without re-evaluation.

Brazilian Registration Holder (BRH) for Finished Drug Products

While API manufacturers can obtain CADIFA directly, the broader framework for importing pharmaceutical products into Brazil requires a Brazilian Registration Holder (BRH) — a Brazilian legal entity holding a valid Autorização de Funcionamento (AFE) from ANVISA. Foreign manufacturers cannot hold ANVISA registrations directly. This applies to the finished drug formulator using the API, not to the API supplier itself.

The New DUIMP Import Portal

In June 2025, ANVISA published RDC No. 977/2025, formalizing the transition to the DUIMP (Declaração Única de Importação) — the Single Import Declaration portal that replaced the legacy SISCOMEX system. The new portal integrates ANVISA's authorizations, customs procedures, and tax requirements into a single system, with ANVISA reporting that import authorization can be released in approximately 10 minutes after registration in some cases.

Brazil Market Context

Shreeji Industries supplies Ferrous Fumarate to formulators in Brazil, so ANVISA's requirements are directly relevant to buyers sourcing for that market.

5. Mexico — COFEPRIS Requirements for API Imports

COFEPRIS and the Regulatory Framework

Mexico's pharmaceutical regulator is COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios), a decentralized body of the Ministry of Health (Secretaría de Salud). Mexico is a full ICH (International Council for Harmonisation) member, meaning its pharmaceutical regulatory standards are aligned with the same ICH Q7, Q3D, and Q3C guidelines that govern US, EU, and Japanese API manufacturing.

Required Documentation for API Import into Mexico

For foreign API manufacturers supplying to Mexico-based drug formulators, the following documentation is required in the drug registration dossier:

• GMP Certificate for the API manufacturing site — issued by a recognized regulatory authority
• Certificate of Pharmaceutical Product (CPP) — for drugs manufactured outside Mexico, with official Spanish translation by a certified translator (Perito traductor)
• Letter of Representation appointing the legal representative of the foreign company in Mexico
• Sanitary Import Permit issued by COFEPRIS for each shipment

2025 GMP Documentation Update

On March 20, 2025, COFEPRIS published in the Official Gazette (DOF) the Agreement Issuing the Guidelines for the Submission of Documents that Guarantee Good Manufacturing Practices for Active Ingredients, Medicines, and Medical Devices. These guidelines apply to new health registrations, extensions, and modifications, and specify exactly which GMP documentation is required for API manufacturers supplying to Mexico-registered products.

Acuerdo de Equivalencia — Mexico's Reliance Pathway

Mexico has one of Latin America's most developed regulatory reliance frameworks. The Acuerdo de Equivalencia (originally 2012, expanded 2020 and 2024, reinforced by the abbreviated pathway agreement of July 18, 2025) allows COFEPRIS to recognize decisions of designated Reference Regulatory Authorities (RRAs) — including FDA and EMA — and issue Mexican registrations based on those foreign assessments, shortening review timelines for manufacturers who have already achieved approval in reference markets.

6. Africa — NAFDAC (Nigeria) and SAHPRA (South Africa)

Nigeria: NAFDAC API Import Requirements

Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC) governs all pharmaceutical imports under the NAFDAC Act CAP N1 (LFN) 2004. No drug shall be manufactured, imported, exported, advertised, sold, distributed, or used in Nigeria unless registered in accordance with this Act.

API Import Permit: All API import into Nigeria requires a dedicated API Import Permit, applied through the Federal Government Single Trade Portal at app.trade.gov.ng/elicense. The permit is issued after review of manufacturing site documentation and payment of appropriate fees, and all approved API import permits must be utilized within the same calendar year of issue.

DMF/ASMF Mandatory: From a NAFDAC industry notice confirmed on the official website: "All pharmaceutical companies who intend to import Active Pharmaceutical Ingredients (API) can import without any categorization henceforth. However, all API import must have Drug Master File (DMF) or Active Substance Master File (ASMF)." The DMF/ASMF must be sent directly or provided in electronic copy to the Director, Drug Evaluation and Research.

Approved API Sources (effective January 2024): NAFDAC published updated guidelines in April 2024 restricting accepted API sources for all dossiers submitted from January 2024 onwards to:

1. WHO Prequalified APIs
2. APIs with Certificates of Suitability to the European Pharmacopoeia (CEP/EDQM)
3. APIs from PIC/S participating authority-certified facilities
4. APIs from Stringent Regulatory Authority (SRA) or WHO Listed Authority (WLA) certified facilities
5. APIs certified by accredited quality control laboratories

NAPAMS Portal: All drug product registration applications are processed on the NAFDAC Automated Product Administration and Monitoring System (NAPAMS) portal at registration.nafdac.gov.ng. Dossier screening clearance is a prerequisite before submission of pharmaceutical applications.

South Africa: SAHPRA API Import Requirements

The South African Health Products Regulatory Authority (SAHPRA) governs pharmaceutical imports under the Medicines and Related Substances Act, No. 101 of 1965 (as amended). Only a South African registered company licensed by SAHPRA can import registered medicines into South Africa.

APIMF (API Master File) Procedure: SAHPRA operates a formal APIMF (API Master File) procedure — document reference SAHPGL-PEM-03, Version 4, updated 23/07/2024 — which allows API manufacturers to submit a confidential technical package directly to SAHPRA, supporting downstream drug product registration applications. Once an APIMF number is allocated for a specific API + manufacturer combination, this approval can be referenced in multiple finished product registration applications without repeating full API quality evaluation.

Establishment Licensing: Any company manufacturing, importing, exporting, distributing, or wholesaling medicines in South Africa must hold an establishment licence from SAHPRA. For API importers and distributors, SAHPRA's Guideline SAHPGL-LIC-05 v1 (April 2024) specifically addresses requirements for wholesaling licences covering scheduled substances used in manufacturing and compounding, referencing the PIC/S Guidelines on Good Distribution Practices for APIs and WHO Import Processes Annex 5 as governing documents.

Responsible Pharmacist: The establishment licence framework requires designation of a Responsible Pharmacist — a registered South African pharmacist who assumes responsibility for regulatory compliance at the importing establishment.

GMP Inspection: SAHPRA conducts GMP inspections at API and finished product manufacturers, both locally and internationally, as part of its market authorization and import control process. FDA or EMA approval does not grant automatic South African registration — a formal SAHPRA application addressing all South African requirements must still be submitted.

7. African Continental Regulatory Harmonization Context

Africa's pharmaceutical market reached approximately $27.65 billion in 2024, projected to reach $36.96 billion by 2033 at a CAGR of 3.3%. Within this, the pharmaceutical molecules/API segment was valued at $13.48 billion in 2024, expected to reach $26.7 billion by 2032 at a CAGR of 9.03%.

The African Medicines Regulatory Harmonization (AMRH) initiative, formalized in 2009 under the African Union's Pharmaceutical Manufacturing Plan for Africa (PMPA), is actively working to address the continent's fragmented national regulatory systems. AUDA-NEPAD (African Union Development Agency) and the WHO serve as Joint Secretariat for the AMRH initiative.

A critical practical data point: of Africa's 54 countries, only five — Tanzania, Ghana, Egypt, Nigeria, and South Africa — currently operate at Maturity Level 3 (ML3) with adequate regulatory capacity across their full scope of products.

What this means for API exporters: Until the AMRH and the African Medicines Agency (AMA) achieve broader continental harmonization, supplying to African markets outside the five ML3 countries requires market-by-market regulatory engagement rather than a single continental compliance strategy.

8. What a Globally Compliant API Exporter Should Prepare

An Indian API manufacturer supplying to all five markets covered in this guide should maintain the following documentation stack as permanent, continuously updated compliance infrastructure:

9. Common Misconceptions About API Import Requirements

Misconception #1: FDA Registration in the US Covers EU Requirements Too

Reality: FDA registration and EU Written Confirmation are entirely separate regulatory requirements under different legal frameworks. Only four countries (US, Japan, Australia, Switzerland) are exempt from the EU Written Confirmation requirement — but that exemption applies to the country's regulatory system equivalence, not to individual manufacturers. An Indian API manufacturer must obtain a DCGI-issued Written Confirmation for EU-bound shipments regardless of FDA registration status.

Misconception #2: If a Formulator Is Registered, the API Supplier Doesn't Need to Be

Reality: The FDORA amendment (December 2022) specifically addressed this gap for the US market — API manufacturers who supply other foreign establishments that ultimately supply the US market must now register with FDA. Similarly, Nigeria's NAFDAC requires a separate API Import Permit at the raw material level, independent of the finished drug product's registration status.

Misconception #3: One GMP Certificate Covers All Markets

Reality: Different markets accept different GMP certificates — FDA inspection certificates are recognized by some markets but not others. EU GMP certificates (EudraGMDP-listed) carry significant weight globally. Nigeria's NAFDAC now requires sourcing from WHO Prequalified, CEP, PIC/S, or SRA/WLA-certified facilities specifically. South Africa's SAHPRA conducts independent inspections and does not automatically recognize FDA or EMA approvals.

Misconception #4: Latin America Is a Single Regulatory Market

Reality: Brazil (ANVISA), Mexico (COFEPRIS), and other LATAM markets each operate independent national regulatory systems with distinct documentation requirements. The CADIFA system is specific to Brazil; Mexico's Acuerdo de Equivalencia reliance pathway is separate from ANVISA's system. A company compliant in Brazil is not automatically compliant in Mexico.

Misconception #5: Africa Has a Single Harmonized API Import Process

Reality: The AMRH initiative is actively working toward harmonization, but as of 2024/2025, only five African countries operate at Maturity Level 3 regulatory capacity. API exporters must comply with each country's national requirements — NAFDAC for Nigeria, SAHPRA for South Africa, KEBS/PPB for Kenya, and so on — rather than a single continental standard.

10. Frequently Asked Questions

11. Sources and References

Regulatory requirements are sourced from official regulatory authority websites and government publications. The Africa market-size estimates come from the market-research publishers in references 18 and 19 and are estimates.